BioPharm International-02-01-2003

Focus on Contract Services

February 15, 2003

by David Wallis, Dechert and Jan Heybroek Whether you're on the inlicensing or outlicensing side of a collaboration, attention must be paid to putting forth the right image and learning about your prospective partners before the alliance is struck.

by John C. Anders, aaiPharma, Inc., Benne F. Parten, Glenn E. Petrie , Robert L. Marlowe , and John E. McEntire Amino acid analysis (AAA) of well-recovered residues offers an easy way to calculate the absorptivity constant for a known protein. The method provides an absolute measure of protein concentration, free from interference from water, excipients, and bound salts. This article demonstrates a qualified method for determining protein content by AAA.

by Jay R. Greenwald, Unisys

by Jill Wechsler Efforts to move vaccines from test stage to commercial production are raising concerns about manufacturing capacity.

by Patrick Clinton , BioPharm International A BioPharm International Forum

Columns and Departments

February 15, 2003

by Vicki Cloutier, Guidant Corporation It's not enough to train your staff ? you have to keep training them. A good learning management system can help.

by David Venables, Q-One Biotech Ltd. Approximately 75 vendors offer biological contract manufacturing services in Europe ? a manageable data set for analyzing the services they provide.

Columns and Departments

February 15, 2003

by Jim Miller, Bio/Pharmaceutical Outsourcing Report Developments in 2002 such as acquisitions, excess manufacturing capacity, and less funding for biotechnology will continue to affect the industry long into the new year.

by Gail Sofer, BioReliance Both the process and the product strongly influence viral inactivation, and unknown or unspecified details ? such as variability in virus titers, measuring devices, calibrations, and protocols ? can all influence log reduction values. This article series covers what you need to know to fully understand the properties of the test article, the viruses inactivated, and the critical control parameters for selected inactivation methods.